Patent Review of Manufacturing Routes to Recently Approved PARP Inhibitors: Olaparib, Rucaparib, and Niraparib

Olaparib, rucaparib, and niraparib are three inhibitors of poly(ADP-ribose) polymerase (PARP) enzymes that have been recently approved for the treatment of ovarian cancer. The current article reviews the patent and journal literature regarding synthetic routes and final forms of these PARP inhibitors.